FDA approves first generic Advair Diskus

4 Feb 2019

Mylan's Wixela Inhub is the first FDA-approved therapeutically equivalent generic of Advair Diskus (fluticasone propionate and salmeterol inhalation powder) for certain patients with asthma or COPD.

Mylan has announced the FDA approval of Wixela Inhub (fluticasone propionate and salmeterol inhalation powder, USP), the first generic of Advair Diskus.

FDA approves first generic Advair Diskus
Wixela Inhub (fluticasone propionate and salmeterol inhalation powder, USP)

Wixela Inhub will launch in the second half of February incorporating the latest safety information required by FDA last month, which prompted an amendment to the label for certain inhaled corticosteroids, including Advair Diskus and any generic versions. Wixela Inhub will be available in the 100 mcg/50 mcg, 250 mcg/50 mcg and 500 mcg/50 mcg strengths for asthma patients and the 250 mcg/50 mcg strength for COPD patients.

Mylan CEO Heather Bresch commented: "Mylan remains steadfast in its efforts to expand patient access to medicines, and the FDA approval of Wixela Inhub reinforces our commitment to provide patients greater choice and lower-cost alternatives. This milestone represents the culmination of an extensive R&D program and Mylan's more than $700 million of investment. We're proud of our Wixela Inhub team, who worked tirelessly and in close collaboration with the FDA to bring this important medicine to market and add it to our growing global portfolio of more than 700 respiratory products. As one of the leading providers of prescription medicines in the US, we continue to execute on our mission and do our part to reduce costs for patients and identify pathways that help increase sustainability for the US healthcare system overall."

Mylan President Rajiv Malik added: "We're pleased to offer the first FDA-approved generic of Advair Diskus, one of the leading treatments for asthma and COPD management today. We've long been confident in the science around this product and are proud of the dedication of our scientific teams to bring Wixela Inhub to market. This complex product required a rigorous R&D program spanning over a decade and close collaboration with FDA to define the regulatory pathway. We also are proud to manufacture Wixela Inhub in our own state-of-the-art plant. This approval reinforces our ongoing commitment to increase access to more affordable treatment options for patients."

"Patients enrolled in clinical trials found Wixela Inhub easy-to-use and highly effective at controlling their asthma in a clinical bioequivalence study. Asthma and respiratory specialists and primary care providers welcome this generic alternative to benefit many patients with asthma and COPD. We have waited for years for generic inhalers to emerge in respiratory medicine," said Edward Kerwin, MD of Crisor, a division of the Clinical Research Institute located in Medford, Ore. and a Clinical Investigator on the Wixela Inhub clinical program.

Advair Diskus had US sales of $4.2 billion for the 12 months ending 30 November 2018, according to IQVIA.

Read More

Related news

Legacy ramps up preparations for new Russian track and trace sterilisation regulations

Legacy ramps up preparations for new Russian track and trace sterilisation regulations

18 Jul 2019

Company to install new inspection cameras with higher resolution to ensure readability of more complex codes demanded by the Russian mandated crypto coding.

Read more 
Combination technique improves polysaccharide characterization

Combination technique improves polysaccharide characterization

17 Jul 2019

The AF4-MALS-RI method makes possible the accurate determination of molecular weight distribution of polysaccharide macromolecules.

Read more 
Lubrizol integrates personal, home and health care divisions

Lubrizol integrates personal, home and health care divisions

16 Jul 2019

The new brand - Lubrizol Life Sciences - aims to maximize client speed-to-market, providing enhanced solutions.

Read more 
Bosch finds buyers for its packaging machinery business

Bosch finds buyers for its packaging machinery business

16 Jul 2019

CVC Capital Partners to " take the business forward in the years ahead, and to make it even more competitive".

Read more 
New state-of-the-art cleanroom boosts production of anticancer drugs

New state-of-the-art cleanroom boosts production of anticancer drugs

15 Jul 2019

The GMP facility has been specifically designed to deliver the next generation of anticancer blockbuster ADC drugs for patients globally.

Read more 
Colorcon chooses the Netherlands for new starch manufacturing plant

Colorcon chooses the Netherlands for new starch manufacturing plant

12 Jul 2019

The plant will provide a secure second source of supply of Starch 1500, Pregelatinized Maize Starch.

Read more 
GSK opens new continuous manufacturing facilities in Singapore

GSK opens new continuous manufacturing facilities in Singapore

11 Jul 2019

Opening of continuous manufacturing facilities and expansion of production building will boost capabilities to accelerate the supply of new breakthrough medicines to patients globally.

Read more 
Eisai collaborates with University of Dundee on cancer drug discovery

Eisai collaborates with University of Dundee on cancer drug discovery

10 Jul 2019

It is hoped that research into PROTACs will lead to new drug discoveries for proteins present in cancer, which are difficult to treat with conventional small molecule inhibitors.

Read more 
Onyx Scientific makes strategic investment in commercial API licence

Onyx Scientific makes strategic investment in commercial API licence

10 Jul 2019

Investment fills the growing gap in the market for manufacturers that have the niche capabilities to deliver small-scale commercial API projects.

Read more 
I Holland to share the science behind tool maintenance

I Holland to share the science behind tool maintenance

9 Jul 2019

Proper maintenance - rather than replacement - of compression tooling will improve profitability.

Read more